



2021 Virtual Congress – Scientific Program

All program timing in CET

Day 1, Friday, May 7th	
12:00-13:15	<i>Industry or non-profit symposium</i>
13:15-13:30	Welcome by Congress chairs
13:30-15:00	Session 1: High risk disease biology
13:30-13:45	Disease risk scoring Hervé Avet-Loiseau , France
13:45-14:00	Genomics of high-risk myeloma TBA
14:00-14:15	IMiDs resistance pathways Keith Stewart , Canada
14:15-15:00	Round table debate <i>Speakers and,</i> Gordon Cook , UK Gareth Morgan , USA
15:00-16:30	Session 2: Immune deregulation in myeloma
15:00-15:15	Role of the microenvironment Irene Ghobrial , USA
15:15-15:30	Mechanisms of resistance to immunotherapy Niels van de Donk , Netherlands
15:30-15:45	Strategies to reverse immune deregulation in myeloma Paola Neri , Canada
15:45-16:30	Round table debate <i>Speakers and,</i> Bertrand Arnulf , France Marc Raab , Germany
16:30-18:00	<i>Plenary satellite symposium</i>
18:00-19:15	Session 3: Plenary lectures
18:00-18:25	Therapy of AL amyloidosis: an update Giampaolo Merlini , Italy
18:25-18:50	Therapy of Waldenstrom macroglobulinemia Steve Treon , USA
18:50-19:15	Round table debate <i>Speakers and,</i> Jorge Castillo , USA
19:15-20:30	<i>Industry or non-profit symposium</i>



Day 2, Saturday, May 8th	
10:00-11:00	Session 4: Snapshot talks (part 1) - Latest data
10:00-10:10	Latest data on HDAC inhibitors Enrique Ocio , Spain
10:10-10:20	Latest data on Targeting SLAMF7 Katia Weisel , Germany
10:20-10:30	Latest data on targeting Bcl2 inhibitors Cyrille Touzeau , France
10:30-10:40	Latest data on biphosphonates Evangelos Terpos , Greece
10:40-10:50	Latest data on antibody drug conjugates Suzan Trudel , Canada
10:50-11:00	Latest data in extra-medullary disease Artur Jurczynszyn , Poland
11:00-12:30	Session 5: Snapshot talks (part 2) - Clinical trials updates
11:00-11:10	IFM 2009 Aurore Perrot , France
11:10-11:20	Carfilzomib, lenalidomide, and dexamethasone plus transplant Andrzej Jakubowiak , USA
11:20-11:30	GRIFFIN Jonathan Kaufman , USA
11:30-11:40	MASTER Luciano Costa , USA
11:40-11:50	IKEMA Tom Martin , USA
11:50-12:00	CANDOR Saad Usmani , USA
12:00-12:30	Q&A
12:30-13:30	<i>Industry symposium</i>
13:30-14:45	Session 6: Therapy of young patients
13:30-13:45	The optimal induction regimen Philippe Moreau , France
13:45-14:00	Role of consolidation (including double auto-transplant) Michele Cavo , Italy
14:00-14:15	Maintenance approaches post-transplant Francesca Gay , Italy
14:15-14:45	Round table debate <i>Speakers and,</i> Peter Sonneveld , Netherlands Joan Blade , Spain Muzaffar Qazilbash , USA



14:45-16:00	Session 7: Therapy of elderly patients
14:45-15:00	IMiD-based approaches Thierry Facon , France
15:00-15:15	Proteasome-based approaches Marivi Mateos , Spain
15:15-15:30	Personalized treatment of the elderly Sonja Zweegman , Netherlands
15:30-16:00	Round table debate <i>Speakers and,</i> Alessandra Larocca , Italy Meral Beksac , Turkey
16:00-17:30	<i>Plenary satellite symposium</i>
17:30-18:30	Session 8: Therapy of smoldering myeloma – a debate
17:30-17:45	Pro S. Vincent Rajkumar , USA
17:45-18:00	Con Xavier Leleu , France
18:00-18:30	Round table debate <i>Speakers and,</i> Shaji Kumar , USA Aurore Perrot , France Rafat Abonour , USA
18:30-19:45	Session 9: Plenary lectures
18:30-18:55	MRD-based therapy: hope, hype, or reality? Jesus San Miguel , Spain
18:55-19:20	How to extend survival at relapse? Meletios Dimopoulos , Greece
19:20-19:45	Round table debate <i>Speakers and,</i> Jean-Luc Harousseau , France Nizar Bahlis , Canada Kwee Yong , UK Saad Usmani , USA
19:45-20:45	<i>Industry or non-profit symposium</i>



Day 3, Sunday, May 9th	
10:00-11:00	ORAL PRESENTATIONS
11:00-12:20	Session 10: Snapshot talks - Practical considerations
11:00-11:10	Practical considerations when using anti-CD38 antibodies Torben Plesner , Denmark
11:10-11:20	Management of cardiovascular adverse events Inger Nijhof , Netherlands
11:20-11:30	MRD monitoring: when, how and in which patient? Bruno Paiva , Spain
11:30-11:40	MGUS diagnosis: a step by step approach Graham Jackson , UK
11:40-11:50	Imaging: the essential work-up Elena Zamagni , Italy
11:50-12:00	COVID-19 vaccination in myeloma Heinz Ludwig , Austria
12:00-12:20	Q&A
12:20-13:30	<i>Industry or non-profit symposium</i>
13:30-14:30	Session 11: Bispecific antibodies forum
13:30-13:45	The case for BCMA as a target Alfred Garfall , USA
13:45-14:00	The case for non-BCMA targets Ajai Chari , USA
14:00-14:30	Round table debate <i>Speakers and,</i> Adam Cohen , USA Hermann Einsele , Germany Luciano Costa , USA
14:30-15:30	Session 12: CAR-T cells forum
14:30-14:45	The case for Ide-Cel Noopur Raje , USA
14:45-15:00	The case for Cilta-Cel Deepu Madduri , USA
15:00-15:30	Round table debate <i>Speakers and,</i> Nina Shah , USA Arnon Nagler , Israel Salomon Manier , France Caitlin Costello , USA



15:30-16:30	Session 13: Novel drugs forum
15:30-15:40	Melflufen-based combinations Paul Richardson, USA
15:40-15:50	Iberdomide-based combinations Sagar Lonial, USA
15:50-16:00	XPO inhibitors Mohamad Mohty, France
16:00-16:30	Round table debate <i>Speakers and,</i> TBA
16:30-18:00	<i>Plenary satellite symposium</i>
18:00-18:30	Session 14: Plenary lecture
18:00-18:30	Multiple myeloma in 2025: the next steps? Kenneth Anderson, USA
18:30-19:00	Awards Ceremony